samedan logo
 
 
spacer
home > pmps > winter 2017 > left to your own devices
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Left to Your Own Devices

It is one of the great conundrums of treating chronic disease: while huge advances have been made in developing innovative therapies, these often go unrealised due to poor adherence by patients not taking their prescribed medicines, continuing to hamper quality healthcare outcomes.

There is a lengthy list of explanations, be they personal, technical or economic, but it is thought that between 33 and 50% of all treatments prescribed for long-term conditions are not taken as recommended. The problem is all too apparent in respiratory disease where, despite significant advances in inhalers for the treatment of asthma and chronic obstructive pulmonary disease (COPD), many patients continue to experience poor disease control.

Studies have shown adherence rates in asthma and COPD vary from 22% up to a frightening 78%. Given that preventer (used daily for control) and reliever (rescue) inhalers are the mainstay of treatment, compliance is vital to enhance quality of life, control symptoms and prevent asthma attacks and COPD exacerbations.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dana Shears has over 25 years’ experience within the drug delivery industry. He has spent the past 11 years with H&T Presspart, part of the Heitkamp and Thumann Group, and is currently the Sales and Business Development Director for the Americas region. Dana is also responsible for commercial activities relating to the electronic MDI platform technology. He received his Bachelor’s Degree in Engineering from West Virginia University, US.

Melissa Manice has a PhD in Clinical and Translational Research from the Icahn School of Medicine at Mount Sinai, US, specialising in Pulmonary Medicine and Biostatistics. Cohero Health is a result of her career in academic clinical medicine, as she saw a deep need to build the solution rather than spend a lifetime studying the problem. Melissa’s years of clinical research and managerial experience have developed important relationships at leading academic medical centres, overseeing the design and execution of large multi-site trials.
spacer
Dana Shears
spacer
spacer
spacer
Melissa Manice
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Juvisé Pharmaceuticals Successfully Complete a €400M Refinancing Following the Acquisition of the Worldwide Rights of Pylera

Paris, France, July 5, 2022: The French speciality pharmaceutical company, Juvisé Pharmaceuticals has recently completed a transaction with AbbVie, regarding the acquisition of the worldwide commercial rights of Pylera®. Details of this transaction remain undisclosed.
More info >>

White Papers

Speciality Logistics Outlook 2015

World Courier

To date, there are more than 178,000 registered clinical trials taking place across the globe, and global pharma’s volume has more than doubled over the last decade. With emerging markets showing explosive predictive growth through 2016, shippers and trial sponsors can expect continued regulatory and overall logistics complexities that foster demand for local, inmarket resources across the globe.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement